HIV抗逆转录病毒治疗每周4天方案的药理学数据:ANRS 162-4D试验
ANRS 162-4D试验在100例成人HIV感染者中评估每周服药4天(ON)后停药3天(OFF)的间歇治疗,96%患者维持病毒学抑制。共分析866份血浆样本,ON期除利匹韦林外药物浓度与7/7天方案无显著差异,OFF期大部分蛋白酶抑制剂浓度低于定量下限,但病毒载量仍不可测。
要点
- 每周4天方案在96%患者中维持48周病毒学抑制。
- ON期除利匹韦林外,药物血浆浓度与每日服药无显著降低。
- OFF期蛋白酶抑制剂浓度多低于定量下限,非核苷类仍可量化。
核心结论
- 尽管OFF期蛋白酶抑制剂和非核苷类逆转录酶抑制剂血浆浓度低或不可测,患者仍维持病毒载量不可测。
研究设计与样本
- 多中心48周研究(ANRS 162-4D试验),纳入100例接受两名核苷类似物加第三种药物(增强型蛋白酶抑制剂或非核苷类逆转录酶抑制剂)治疗的成人HIV感染者。
- 在基线(W0,7/7策略)、W16和W40(ON期)及W4、W8、W12、W24、W32和W48(OFF期)采集血样分析药物血浆浓度。
主要发现
- 共分析866份样本。
- ON期(服药4天)血浆浓度与7/7天治疗相比无统计学显著降低,仅利匹韦林降低30 ng/mL(P=0.003)。
- OFF期与ON期相比,除依曲韦林(n=5,P=0.062)外,血浆浓度显著降低。
- ON期87.1%的浓度高于理论疗效阈值(阿扎那韦92.1%、达芦那韦51.1%、洛匹那韦62.5%、依非韦伦94.4%、依曲韦林100%、利匹韦林94.9%)。
- OFF期21.8%的浓度高于理论疗效阈值(阿扎那韦1.4%、达芦那韦0.0%、洛匹那韦0.0%、依非韦伦16.0%、依曲韦林92.6%、利匹韦林39.0%)。
关键数值与推荐
- OFF期85.8%的蛋白酶抑制剂浓度低于定量下限,而98.0%的非核苷类逆转录酶抑制剂浓度可量化。
临床怎么用
- 每周4天间歇方案在部分患者中可维持病毒学抑制,但需注意利匹韦林在ON期浓度降低及OFF期蛋白酶抑制剂浓度普遍低下的药代动力学特点。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Few data are available on plasma concentrations of antiretroviral therapy (ARV) during intermittent treatment. OBJECTIVE: To compare plasma concentrations in OFF vs ON treatment periods at several time points during treatment. METHODS: During a successful 48-week multicenter study (ANRS 162-4D trial) of 4 days with treatment (ON) followed by 3 days without treatment (OFF) in adults treated by two nucleoside analogues and a third agent belonging to a boosted protease-inhibitor (PI, darunavir [DRV], atazanavir [ATV], lopinavir [LPV]) or a non-nucleoside-reverse-transcriptase inhibitor (NNRTI, efavirenz [EFV], etravirine [ETR], rilpivirine [RPV]) conducted in 100 patients (96% success), we determined the plasma concentrations of ARV. Blood samples were collected for analysis at inclusion (W0, 7/7 strategy for all patients), W16 and W40 (ON) and at W4, W8, W12, W24, W32 and W48 (OFF). RESULTS: A total of 866 samples was analysed. Plasma concentrations were not statistically lower after 4 days (ON) vs 7/7 days of treatment except for RPV (-30 ng/mL at 4/7, P = 0.003). Significant lower plasma concentrations were observed for OFF vs ON except for ETR (n = 5, P = 0.062). Overall, 87.1% of ON concentrations (ATV 92.1%, DRV 51.1%, LPV 62.5%, EFV 94.4%, ETR 100% and RPV 94.9%) and 21.8% of OFF concentrations (ATV 1.4%, DRV 0.0%, LPV 0.0%, EFV 16.0%, ETR 92.6% and RPV 39.0%) were above the theoretical limit of efficacy of the molecule. In the OFF period, 85.8% of PI concentrations were under the limit of quantification, while 98.0% of NNRTI concentrations were quantifiable. CONCLUSION: Despite low/undetectable PI/NNRTI plasma concentrations in the OFF period, patients maintained an undetectable viral load. The mechanistic explanation should be investigated.
引用
- Abe E, Assoumou L, de Truchis P, et al. Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial). Br J Clin Pharmacol. 2020. PMID: 33010058. doi:10.1111/bcp.14586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。